Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trialRobert I. Haddad, Marshall R. Posner, Anne O’Neill et al.|The Lancet Oncology|2013Cited by 748
Trastuzumab for the Treatment of Salivary Duct CarcinomaSewanti Limaye, Robert I. Haddad, Marshall R. Posner et al.|The Oncologist|2013Cited by 185
Phase 1b, multicenter, single blinded, placebo‐controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapySewanti Limaye, Barbara A. Murphy, Robert I. Haddad et al.|Cancer|2013Cited by 126
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II StudyGlenn J. Hanna, Jochen H. Lorch, Naifa L. Busaidy et al.|Clinical Cancer Research|2018Cited by 125
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)Sewanti Limaye, Robert I. Haddad, Sarah Riley et al.|Oral Oncology|2013Cited by 59